Delivering the
Health Benefits
of Tocotrienols

  • Mr. Craig Newton appointed Chief Operating Officer
  • Brings extensive marketing, sales and commercialisation experience from the international life sciences industry
  • Appointment bolsters Gordagen’s plans for launch of two nutraceutical products in the US

23 May 2017, Melbourne, Australia
- Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing tocotrienols, today announced that Mr. Craig Newton will be joining the Company as Chief Operating Officer.

Mr Newton is an experienced life sciences commercialisation professional with extensive experience in business development, marketing and sales of pharmaceuticals, diagnostics and medical devices. He will be responsible for Gordagen’s business development, including major international licensing and partnering deals for Gordagen’s nutraceutical and pharmaceutical portfolios.

Dr Glenn Tong, Gordagen’s CEO and Managing Director, commented:
“With commercial launches in the USA expected for both our heart health and exercise nutraceutical products , Craig’s international life sciences commercialisation experience is going to be crucial. Adding value to Gordagen in our build up towards a possible future IPO will be our priority in coming months.”

“I am very excited about joining Gordagen’s Management Team at this inflection point in the Company’s trajectory. Two new products are about to enter the largest nutraceutical market in the world and there is great potential in the Company’s prescription medicines pipeline that I am also looking forward to crystallising,” commented Mr. Craig Newton, Gordagen’s new Chief Operating Officer.

Craig has more than 25 years' commercial experience in the pharmaceutical, biotechnology and medical device industries gained within both large companies and small start-ups, in Australasia, Asia and Europe. Previous positions have included being Head of Sales and Marketing at Bio Nova International where he managed the Company's global commercial presence, Business Unit Manager for Serono's $50m IVF business in the UK and Chief Operating Officer at ASX-listed Cryptome Pharmaceuticals Ltd. Craig has a Bachelor of Applied Science in Medical Technology and postgraduate Management and Marketing qualifications.


Dr. Douglas Pretsell Dr. Glenn Tong

Ph: +61 (0) 409 908 553

CEO and Managing Director
Ph: +61 (0) 412 193 350

Download the full announcement (PDF, 411kb)